• 1
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 32846.
  • 2
    Australian Bureau of Statistics (ABS). National health survey 2001: ABS cat. no. 4364.0. Canberra: Commonwealth of Australia; 2002.
  • 3
    Choi HK, Hernan MA, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 11737.
  • 4
    Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 14858.
  • 5
    Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997; 26: 794804.
  • 6
    Georgescu L, Paget SA. Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? Drug Saf 1999; 20: 47587.
  • 7
    Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 1993; 20: 63944.
  • 8
    Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, et al. Long term methotrexate use in rheumatoid arthritis: 12 year follow up of 460 patients treated in community practice. J Rheumatol 2000; 27: 186471.
  • 9
    Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958; 9: 1756.
  • 10
    World Health Organization. International Classification of Disease. Geneva: WHO; 1977.
  • 11
    World Health Organization. International Classification of Diseases for oncology. Geneva: WHO; 1976.
  • 12
    CoteRA, editor. Systematized nomenclature of medicine. Skokie (IL): College of American Pathologists; 1980.
  • 13
    Jeannou J, Goupille P, Valat JP. Association of methotrexate, rheumatoid arthritis, and melanoma in 2 patients [letter]. J Rheumatol 1997; 24: 14445.
  • 14
    Ishiyama K, Suwa A, Goto M, Hirakata M, Inoue K, Hara M, et al. Malignant melanoma in a patient with rheumatoid arthritis [letter]. Clin Exp Rheumatol 1998; 16: 507.
  • 15
    Potter T, Hardwick N, Mulherin D. Multiple malignant melanomas in a patient with RA treated with methotrexate [letter]. J Rheumatol 1998; 25: 22823.
  • 16
    Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ. Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 275764.
  • 17
    Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries. Cancer in Australia 2001. In: Cancer series, AIHW. Canberra: AIHW; 2004.
  • 18
    Briggs AM, March L, Lassere M, Reid C, Portek I, Wengier L, et al. Baseline comorbidity in Australian patients receiving biological therapy for rheumatoid arthritis [abstract]. Intern Med J 2007; 37 Suppl 2: A38.
  • 19
    Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG. Incidence of cancer among patients with rheumatoid arthritis. J Nat Cancer Inst 1993; 85: 30711.
  • 20
    Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A: 17537.
  • 21
    Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 21305.
  • 22
    Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5,356 patients following organ transplantation. Br J Dermatol 2000; 143: 5139.
  • 23
    Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979; 2: 14616.
  • 24
    Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, et al. Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer 1995; 60: 1839.
  • 25
    Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61: 2748.
  • 26
    Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 17786.
  • 27
    Moloney FJ, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154: 498504.
  • 28
    Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a followup study. Transplantation 1996; 61: 71521.
  • 29
    Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10-year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996; 35: 73845.
  • 30
    Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999; 26: 170514.
  • 31
    Isomaki H, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia, and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31: 6916.
  • 32
    Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB, and the Rheumatoid Arthritis Azathioprine Registry Steering Committee. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 1991; 18: 80914.
  • 33
    Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497502.
  • 34
    Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 174051.
  • 35
    Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J, and the Investigators of the Club Rhumatismes et Inflammation. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 390915.
  • 36
    Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998; 317: 1801.
  • 37
    Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 2001; 21: 10611.
  • 38
    Kauppi M, Pukkala E, Isomaki H. Excess risk of lung cancer in patients with rheumatoid arthritis [letter]. J Rheumatol 1996; 23: 14845.
  • 39
    Chen CY, Chen YM, Yen SH, Perng RP. Lung cancer associated with rheumatoid arthritis does not shorten life expectancy. J Chin Med Assoc 2005; 68: 21620.
  • 40
    Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78: 449.
  • 41
    Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 14216.